# Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above

> **NCT05636436** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **MAXVAX Biotechnology Limited Liability Company** · enrollment: 132 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Low Dose Recombinant Herpes Zoster Vaccine (CHO cells)
- **BIOLOGICAL:** High Dose Recombinant Herpes Zoster Vaccine (CHO cells)
- **BIOLOGICAL:** Low dose adjuvant
- **BIOLOGICAL:** High dose adjuvant
- **BIOLOGICAL:** Positive control
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05636436
- **Lead sponsor:** MAXVAX Biotechnology Limited Liability Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-07
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2024-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05636436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05636436, "Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05636436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*